中国 深圳 福田区益田路6001号太平金融大厦11、12楼 邮政编码：518038 11、12/F, TaiPing Finance Tower,Yitian Road 6001, Futian District, ShenZhen, P.R.China 518038 电话（Tel）：（0755） 88265064，88265288 传真（Fax）：（0755）88265537 网址（Website）：http://www.shujin.cn 广东信达律师事务所 关于深圳市信宇人科技股份有限公司 2025年第三次临时股东会之 法律意见书 信达科会字（2025）第059号 1 所发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗漏，并 承担相应法律责任。 基于上述，根据《股东会规则》第六条的规定，信达律师按照律师行业公认的 业务标准、道德规范和勤勉尽责精神，对本次股东会的相关事宜出具如下见证意见： 一、本次股东会的召集与召开程序 （一）本次股东会的召集 公司董事会于2025年11月22日在巨潮资讯网站上刊载了《深圳市信宇人科技股 份有限公司关于召开2025年第三次临时股东会的通知》（以下简称"《股 ...

证券代码：688573 证券简称：信宇人 公告编号：2025-051 深圳市信宇人科技股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 会议召开和出席情况 重要内容提示： 本次会议是否有被否决议案：无 （一） 股东会召开的时间：2025 年 12 月 8 日 （二） 股东会召开的地点：惠州仲恺高新区东江高新科技产业园兴启西路 3 号 惠州信宇人一号会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 69 | | --- | --- | | 普通股股东人数 | 69 | | 2、出席会议的股东所持有的表决权数量 | 45,526,635 | | 普通股股东所持有表决权数量 | 45,526,635 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 48.2821 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 48.2821 | 注：截 ...

信宇人公告，公司募投项目"惠州信宇人研发中心建设项目"新增实施主体为母公司深圳市信宇人科技股 份有限公司，同时新增实施地点为深圳市龙岗区。 ...

Core Viewpoint - The integration of basic medical insurance and commercial health insurance is driving innovation in drug research and application in China, with significant advancements in the pharmaceutical industry over the past decade [1] Group 1: Drug Development and Market Trends - From January to October, China has authorized over 700 innovative drugs overseas, with a total value exceeding $100 billion [1] - The 2025 National Medical Insurance Drug List includes 114 new drugs, of which 50 are first-class innovative drugs, showing an overall success rate of 88%, up from 76% in 2024 [1] - The first version of the commercial health insurance innovative drug list includes 19 drugs, covering treatments for CAR-T, neuroblastoma, Gaucher disease, and Alzheimer's disease [1][4] Group 2: Characteristics of the Commercial Health Insurance Drug List - The commercial health insurance drug list emphasizes support for innovation, including advanced therapies such as CAR-T, TCE therapy, and bispecific antibodies [4] - It addresses key areas of concern, including drugs for Alzheimer's disease and rare diseases prevalent in children, reflecting the aging population trend [4] - The list delineates the boundary between basic medical insurance and commercial insurance, with basic insurance focusing on safe and effective drugs, while commercial insurance prioritizes innovative and cutting-edge medications [4] Group 3: Collaboration and Future Outlook - Companies like 合源生物科技股份有限公司 are actively collaborating with the National Medical Insurance Bureau and commercial health insurance providers to implement related plans and enhance patient awareness of health insurance [5][6] - The commercial health insurance innovative drug list is seen as a significant step in supporting the development of innovative drugs and establishing a multi-tiered medical payment system [6] - The 2025 National Medical Insurance Drug List includes drugs that fill gaps in basic insurance coverage for major diseases and rare conditions, increasing the total number of drugs to 3,253 [6]

Group 1 - The company emphasizes the importance of shareholder rights and acknowledges that secondary market performance is significantly influenced by macroeconomic conditions, market preferences, and investor expectations [1] - The company plans to leverage a "equipment + technology + materials" integrated approach to further develop its capabilities in high-end intelligent manufacturing equipment research, production, and sales [1] - The company aims to improve its operational performance to provide better returns to shareholders in the future [1]

Core Viewpoint - The company is experiencing a significant increase in orders and is actively working to expand its production capacity to meet future market demand for lithium battery equipment, particularly driven by the growth in the electric vehicle and energy storage markets [1] Group 1: Company Operations - The company currently has a large number of orders on hand, with production capacity utilization remaining at a high level [1] - The construction progress of the second production park in Huizhou is being accelerated to alleviate delivery pressure caused by the substantial increase in orders [1] Group 2: Market Demand - There is a clear growth in demand for lithium batteries from downstream markets, particularly in the electric vehicle and energy storage sectors [1] - The demand for lithium battery equipment is expected to continue to grow over the next 2-3 years, driven by the replacement of retired equipment and production line upgrades [1]

深圳市信宇人科技股份有限公司 2025 年第三次临时股东会会议资料 证券代码：688573 证券简称：信宇人 深圳市信宇人科技股份有限公司 ShenzhenXinyurenTechnologyCo.,Ltd. 2025 年第三次临时股东会 会议资料 二〇二五年十二月 | 2025 | 年第三次临时股东会会议议程 4 | | --- | --- | | 2025 | 年第三次临时股东会会议议案 6 | | | 议案一：《关于聘任会计师事务所的议案》 6 | 深圳市信宇人科技股份有限公司 2025 年第三次临时股东会会议资料 2025 年第三次临时股东会会议须知 为维护广大投资者的合法权益，保障股东在本次股东会期间依法行使权利， 根据《公司法》、中国证监会《上市公司股东会规则》和公司《股东会议事规则》 等有关规定，特制定本会议须知： 一、公司负责本次股东会的议程安排和会务工作，为确认出席会议的股东或 其代理人或其他出席者的出席资格，会议工作人员将对出席会议者的身份进行必 要的核对工作，请被核对者给予配合。 二、出席会议的股东及股东代理人须在会议召开前半小时到会议现场办理签 到手续，并按规定出示本人有效身份证或营业 ...

Core Viewpoint - The company XinYuren experienced a decline in stock price by 1.47% on November 26, with a trading volume of 36.71 million yuan, indicating potential investor concerns regarding its financial performance and market position [1]. Financing Summary - On November 26, XinYuren had a financing buy-in amount of 7.41 million yuan, with a net financing buy of 3.06 million yuan after 4.35 million yuan in financing repayments. The total financing and margin balance reached 90.61 million yuan, accounting for 7.25% of its market capitalization, which is above the 50th percentile level over the past year, indicating a relatively high financing level [1]. - The company had no short selling activity on the same day, with a short selling balance of 0.00 shares, placing it in the 90th percentile level over the past year, suggesting a lack of bearish sentiment among investors [1]. Business Performance - As of September 30, the number of shareholders for XinYuren increased by 5.27% to 8,315, while the average circulating shares per person decreased by 2.77% to 6,400 shares [2]. - For the period from January to September 2025, XinYuren reported a revenue of 94.75 million yuan, a significant year-on-year decrease of 50.12%. The net profit attributable to shareholders was -15.7 million yuan, reflecting a drastic decline of 106.31% compared to the previous year [2]. Dividend and Shareholding Structure - Since its A-share listing, XinYuren has distributed a total of 19.37 million yuan in dividends [3]. - As of September 30, 2025, among the top ten circulating shareholders, Yuanxin Yongfeng High-end Manufacturing A (006969) emerged as the eighth largest shareholder with 364,100 shares, marking its entry as a new shareholder. Meanwhile, Zhonghai Energy Strategy Mixed (398021) and Jinying Reform Dividend Mixed (001951) exited the top ten list [3].

Group 1 - The company, Xinyu, stated on November 24 that it will disclose the number of shareholders at the end of the reporting period in its regular reports to ensure all investors receive information equally [2]

Group 1 - The company will hold its third extraordinary general meeting of shareholders on December 8, 2025, at 14:30 [2][5] - The meeting will take place at the company's conference room located in Huizhou [2] - Shareholders can vote through the Shanghai Stock Exchange's online voting system on the day of the meeting [3][4] Group 2 - The company plans to appoint Shanghai Huikai Certified Public Accountants as its new auditing firm for the 2025 fiscal year, replacing Zhengdan Zhiyuan [20][21] - The change in auditing firms is aimed at better aligning with the company's future business development and ensuring effective audit arrangements [21][31] - The proposed auditing fee for 2025 is set at 1.2 million yuan, which includes 250,000 yuan for internal control auditing [30]